New Science Ventures

Founded 2004
Founders Somu Subramaniam

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 61
Average round size
info
The average size of a deal this fund participated in
$18M
Portfolio companies 45
Rounds per year 3.59
Lead investments 16
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.33
Exits 15
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Medical Device
Summary

In 2004 was created New Science Ventures, which is appeared as VC. The main office of represented VC is situated in the New York. The company was established in North America in United States.

The fund was created by Somu Subramaniam. We also calculated 8 valuable employees in our database.

Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Light Sciences Oncology, BioVex, Juventas Therapeutics We can highlight the next thriving fund investment areas, such as Medical Device, Pharmaceutical. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

Considering the real fund results, this VC is 16 percentage points more often commits exit comparing to other organizations. The fund is generally included in 2-6 deals every year. Deals in the range of 10 - 50 millions dollars are the general things for fund. Comparing to the other companies, this New Science Ventures performs on 10 percentage points less the average number of lead investments. The top amount of exits for fund were in 2015. The important activity for fund was in 2016. Despite it in 2019 the fund had an activity.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the New Science Ventures, startups are often financed by Oxford Bioscience Partners, Easton Capital, Triathlon Medical Venture Partners. The meaningful sponsors for the fund in investment in the same round are Forbion Capital Partners, Easton Capital, Triathlon Medical Venture Partners. In the next rounds fund is usually obtained by Easton Capital, Oxford Bioscience Partners, OrbiMed.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of New Science Ventures:
Typical Co-investors
New Science Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after New Science Ventures:

Funds with similar focus

Funds from United States, New York
Funds with similar focus located in United States, New York:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
River SaaS Capital United States, Westlake
Coral Reef IO United Kingdom, London
Varsity Ventures United States, Stanford
Money Forward Japan, Chiyoda
Q Investments United States, Fort Worth
Asia Capital Sri Lanka, Colombo
Cognosante United States, McLean
Vertex Asia Fund Russia, Moscow
Falcon Capital United Kingdom, London
Capital Medica Ventures Japan, Chiyoda
Lotus -
Zhongyi Venture Capital -
Promus Capital United States, Chicago
RRC Group Russia, Moscow
Baichuan Huida Touzi China, Guangdong
Xuebao No.1 China, Haidian
Actium Funds United States, Salt Lake City
Koudai Jianzhi China, Guangzhou
Co-Share capital China, Guangzhou
Xuwei Investment China, Shanghai

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Phase Four

Aerospace
Innovation Management
Space Travel
1
$26M11 Jun 2021 United States, " United States"}

Aerospace
Information Technology
Satellite Communication
1
$49M31 Mar 2020 United States, " United States"}

NorthSea Therapeutics

Biotechnology
Health Care
Therapeutics
1
$42M08 Jan 2020 Netherlands, " The Netherlands"}

DUST Identity

Cyber Security
Information Technology
Internet of Things
Nanotechnology
Security
Software
Supply Chain Management
1
$10M17 Jul 2019 United States, Boston

PlanetIQ

Information Technology
1
$18M10 Jul 2019 United States, Golden

Paradigm Diagnostics

Biotechnology
Genetics
1
$15M21 May 2019 United States, Phoenix

BrightVolt

Battery
Electronics
Manufacturing
n/a
$6M20 Jan 2019 United States, " United States"}

DUST Identity

Cyber Security
Information Technology
Internet of Things
Nanotechnology
Security
Software
Supply Chain Management
1
$2M14 Nov 2018 United States, Boston

Svelte Medical Systems

Health Care
Medical
Medical Device
1
$22M31 Oct 2018 United States, " United States"}
News
Isorg Raises €16M in Series C Financing

– Isorg from Limoges, France develops Organic Photodetectors (OPDs) and large-area image sensors.
– The company raised €16M in series C financing.
– Two major industrial investors – Sumitomo Chemical Co. Ltd and Mitsubishi Corporation participated in the round.
– Greece-based Integrated Systems Development SA and five new French investors represented by fund manager Financière Fonds Privés also joined the round.
– Legacy shareholders Bpifrance, through its large venture funds, New Science Venture, CEA Investment and Sofimac Group (Limousin Participations) also contributed.

Phase Four Raises $26m Series B led by New Science Ventures

– Phase Four announced a $26m Series B investment round.
– The round was led by New Science Ventures LLC.
– The new capital follows a year of significant growth for Phase Four.
– NSV is a leading venture capital firm focused on building companies that leverage breakthrough science to create extraordinary value.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent New Science Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: